U.S. Markets open in 4 hrs 44 mins

Biofrontera AG (BFRA)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
7.11-0.10 (-1.39%)
At close: 4:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close7.21
Bid0.00 x 900
Ask0.00 x 3100
Day's Range7.10 - 7.24
52 Week Range5.27 - 55.00
Avg. Volume593,587
Market Cap169.885M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.76
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est12.00

    Biofrontera AG to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / November 12, 2020 / Biofrontera AG (NASDAQ:BFRA) will be discussing their earnings results in their 2020 Third Quarter Earnings call to be held on November 12, 2020 at 2:00 PM Eastern Time.

  • Biofrontera AG resolves mandatory conversion of subordinated mandatory convertible bonds

    Biofrontera AG resolves mandatory conversion of subordinated mandatory convertible bonds

    Leverkusen, Germany, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, has issued a 1.00% qualified subordinated mandatory convertible bond 2020/2021 (ISIN: DE000A3E4548 / WKN: A3E454) in August 2020. Within the scope of the issuance, 2,638,150 qualified subordinated mandatory convertible bearer bonds ("Bonds") with a nominal value of EUR 3.00 each were issued. The term of the Bonds began on August 20, 2020 and will end on December 20, 2021. Pursuant to Section 8 (2) of the Bond terms and conditions, however, the Company is entitled to a mandatory conversion at any time without limitation in time after the price of the Company's share has exceeded EUR 4.50 ("Mandatory Conversion Trigger Price"). The Mandatory Conversion Trigger Price was exceeded after the commencement of the term of the Bonds.The Management Board with the approval of the Supervisory Board decided today to exercise the right to mandatory conversion pursuant to Section 8 (2) of the Bond terms and conditions. The notice of mandatory conversion will be published shortly in the Federal Gazette.Biofrontera AG, Hemmelrather Weg 201, 51377 LeverkusenISIN: DE0006046113 WKN: 604611Contact: Biofrontera AG Tel.: +49 (0214) 87 63 2 0, Fax.: +49 (0214) 87 63 290 E-mail: ir@biofrontera.com Forward Looking Statements: Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995 regarding the public offering and the intended use of proceeds from the offering. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimate" and "intend," among others. Such forward-looking statements are based on the currently held beliefs and assumptions of the management of Biofrontera AG, which are expressed in good faith and, in their opinion, reasonable. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, financial condition, performance, or achievements of the Company, or industry results, to differ materially from the results, financial condition, performance or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and other factors are set forth in the Registration Statement on Form F-1 filed with the SEC, including in the section "Risk Factors," and in future reports filed with the SEC. Given these risks, uncertainties and other factors, prospective investors are cautioned not to place undue reliance on these forward-looking statements. The Company does not undertake an obligation to update or revise any forward-looking statement.

  • Benzinga

    Biofrontera: Q3 Earnings Insights

    Shares of Biofrontera (NASDAQ:BFRA) moved higher by 0.1% in pre-market trading after the company reported Q3 results.Quarterly Results Earnings per share were flat 0.00% year over year to ($0.00), which beat the estimate of ($0.34).Revenue of $5,508,000 declined by 1.98% from the same period last year, which missed the estimate of $5,900,000.Looking Ahead Earnings guidance hasn't been issued by the company for now.View more earnings on BFRABiofrontera hasn't issued any revenue guidance for the time being.Recent Stock Performance Company's 52-week high was at $55.00Company's 52-week low was at $5.27Price action over last quarter: down 32.85%Company Profile Biofrontera AG is active in the field of healthcare in the United Kingdom. It manufactures pharmaceutical products, especially medical cosmetics and dermatological drugs for the care and treatment of skin diseases. Its suite of products includes the prescription drugs Ameluz and BF-RhodoLED, for the treatment of actinic keratosis and Belixos, for the regenerative care of reddened and inflamed skin.See more from Benzinga * Click here for options trades from Benzinga * Earnings Scheduled For November 11, 2020(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.